🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8,395 results for “La” Clear

  1. Aflibercept 8 mg

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  2. Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  3. Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose

    Regeneron UK Limited

    Macular Edema Secondary to Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  4. Aglatimagene besadenovec + valacyclovir

    Candel Therapeutics

    Prostate Cancer

    phase 3 mab active

    1 trial

  5. Alecensa 150 mg hard capsules, IMFINZI 50 mg/mL concentrate for solution for infusion.

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  6. Alecensa 150 mg hard capsules, VINORELBINE, Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin ACTAVIS 10 mg/ml concentrat pentru soluţie perfuzabilă, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Alecensa 150 mg hard capsules

    Hoffmann-La Roche

    Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  7. Alectinib

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  8. Alectinib - Usual

    Lxo Ireland Designated Activity Company

    ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  9. Aleglitazar

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

    phase 3 small molecule completed

    2 trials

  10. Alemtuzumab

    United Therapeutics Europe Ltd

    Kidney Transplantation

    phase 3 small molecule completed

    1 trial

  11. Alirocumab

    Regeneron UK Limited

    Hypercholesterolaemia

    phase 3 small molecule completed

    2 trials

  12. Alirocumab

    Regeneron UK Limited

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule completed

    1 trial

  13. Alirocumab

    Sanofi Pasteur

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule completed

    1 trial

  14. Alirocumab SAR236553

    Regeneron UK Limited

    Hypercholesterolaemia

    phase 3 small molecule completed

    1 trial

  15. Alisertib

    Takeda

    Relapsed Peripheral T-Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  16. Ambrisentan Viatris 5 mg film-coated tablets, Placebo de AMBRISENTAN VIATRIS 5 mg - composition: cellulose microcristalline; lactose monohydraté; silice colloïdale anhydre; stéarate de magnésium (vegetable origin); opadry II 85G94065 PINK; eau purifiée, TADALAFIL

    Pari Pharma GmbH

    Pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  17. Amchafibrin

    Lxo Ireland Designated Activity Company

    Osteoarthritis, Knee

    phase 3 small molecule completed

    1 trial

  18. Amifampridine Phosphate

    CATALYST PHARMACEUTICALS, INC.

    Lambert Eaton Myasthenic Syndrome

    phase 3 small molecule completed

    2 trials

  19. Amikacin Inhalation Solution (BAY41-6551)

    Nektar Therapeutics UK Limited

    Pneumonia, Bacterial

    phase 3 small molecule completed

    1 trial

  20. Amisulpride, DEXAMETHASONE PHOSPHATE, ONDANSETRON

    Lacuna Pharma Pty Ltd

    post-operative nausea and vomiting in pediatric patients

    phase 3 small molecule active

    1 trial

  21. Amivantamab

    Janssen Cilag International NV

    Colorectal Neoplasms

    phase 3 mab active

    1 trial

  22. Amlitelimab, Placebo, -, TACROLIMUS , PIMECROLIMUS , Amlitelimab

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  23. Amlitelimab, Placebo, Amlitelimab, PIMECROLIMUS , -, TACROLIMUS

    Sanofi-aventis Healthcare Pty Ltd

    atopic dermatitis

    phase 3 small molecule active

    1 trial

  24. Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources